The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations
Open accessAbstract
Costimulatory signals are required to achieve robust chimeric antigen receptor (CAR) T cell expansion, function, persistence and antitumor activity. These can be provided by incorporating intracellular signalling domains from one or more T cell costimulatory molecules, such as CD28 or 4‐1BB, into the CAR. The selection and positioning of costimulatory domains within a CAR construct influence CAR T cell function and fate, and clinical experience of autologous anti‐CD19 CAR T cell therapies suggests that costimulatory domains have differential impacts on CAR T cell kinetics, cytotoxic function and potentially safety profile. The clinical impacts of combining costimulatory domains and of alternative costimulatory domains are not yet clearly established, and may be construct‐ and disease‐specific. The aim of this review is to summarise the function and effect of established and emerging costimulatory domains and their combinations within CAR T cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., Jäger, U., Jaglowski, S., Andreadis, C., Westin, J. R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1804980 · Cited by 4,112
Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675
Molecular mechanisms of T cell co-stimulation and co-inhibition
Chen, L., & Flies, D. B. (2013) · Nature Reviews Immunology · doi:10.1038/nri3405 · Cited by 3,114
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Park, J. H., Rivière, I., Gonen, M., Wang, X., Sénéchal, B., Curran, K. J., Sauter, C., Wang, Y., Santomasso, B., Mead, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709919 · Cited by 2,688
Chimeric antigen receptor T-cell therapy—assessment and management of toxicities
Neelapu, S. S., Tummala, S., Kebriaei, P., Wierda, W., Gutierrez, C., Locke, F. L., Komanduri, K. V., Lin, Y., Jain, N., Daver, N., et al. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.148 · Cited by 2,438
Locke, F. L., Ghobadi, A., Jacobson, C. A., Miklos, D. B., Lekakis, L. J., Oluwole, O. O., Lin, Y., Braunschweig, I., Hill, B. T., Timmerman, J. M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30864-7 · Cited by 2,286
Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063842 · Cited by 2,164 · cited 1×
“However, activation of costimulatory receptors can lead to unbridled inflammatory responses with life-threatening consequences.(7) An understanding of T cell costimulation is therefore critical for the development of safe and effective adoptive T cell therapies, including those employing chimeric antigen receptors CAR…”
BackgroundLong, A. H., Haso, W. M., Shern, J. F., Wanhainen, K. M., Murgai, M., Ingaramo, M., Smith, J. P., Walker, A. J., Kohler, M. E., Venkateshwara, V. R., et al. (2015) · Nature Medicine · doi:10.1038/nm.3838 · Cited by 1,815
Eshhar, Z., Waks, T., Gross, G., & Schindler, D. G. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.2.720 · Cited by 1,658
Gross, G., Waks, T., & Eshhar, Z. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.24.10024 · Cited by 1,590
Kawalekar, O. U., O’Connor, R. S., Fraietta, J. A., Guo, L., McGettigan, S. E., Posey, A. D., Patel, P. R., Guedan, S., Scholler, J., Keith, B., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.01.021 · Cited by 1,230
The Principles of Engineering Immune Cells to Treat Cancer
Lim, W. A., & June, C. H. (2017) · Cell · doi:10.1016/j.cell.2017.01.016 · Cited by 1,080
Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor
Maher, J., Brentjens, R. J., Gunset, G., Rivière, I., & Sadelain, M. (2002) · Nature Biotechnology · doi:10.1038/nbt0102-70 · Cited by 1,034
Savoldo, B., Ramos, C. A., Liu, E., Mims, M. P., Keating, M. J., Carrum, G., Kamble, R. T., Bollard, C. M., Gee, A. P., Mei, Z., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46110 · Cited by 1,023
CD28 Costimulation: From Mechanism to Therapy
Esensten, J. H., Helou, Y. A., Chopra, G., Weiss, A., & Bluestone, J. A. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.020 · Cited by 937 · cited 14×
“While some costimulatory molecules are expressed only upon T cell activation, CD28 is expressed by both resting and recently activated T cells.(3) The potency of unrestrained CD28 signalling is exemplified by the”
BackgroundInfluentialZhao, Z., Condomines, M., van der Stegen, S. J. C., Perna, F., Kloss, C. C., Gunset, G., Plotkin, J., & Sadelain, M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.09.004 · Cited by 843
Imai, C., Mihara, K., Andreansky, M., Nicholson, I. C., Pui, C.-H., Geiger, T. L., & Campana, D. (2004) · Leukemia · doi:10.1038/sj.leu.2403302 · Cited by 840
Kagoya, Y., Tanaka, S., Guo, T., Anczurowski, M., Wang, C.-H., Saso, K., Butler, M. O., Minden, M. D., & Hirano, N. (2018) · Nature Medicine · doi:10.1038/nm.4478 · Cited by 622
The significance of OX40 and OX40L to T‐cell biology and immune disease
Croft, M., So, T., Duan, W., & Soroosh, P. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00766.x · Cited by 604
Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation
Guedan, S., Posey, A. D., Shaw, C., Wing, A., Da, T., Patel, P. R., McGettigan, S. E., Casado-Medrano, V., Kawalekar, O. U., Uribe-Herranz, M., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.96976 · Cited by 580
A NEW ANALYSIS OF ALLOGENEIC INTERACTIONS
Lafferty, K., & Cunningham, A. (1975) · Australian Journal of Experimental Biology and Medical Science · doi:10.1038/icb.1975.3 · Cited by 556
Finney, H. M., Lawson, A. D. G., Bebbington, C. R., & Weir, A. N. C. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.6.2791 · Cited by 546
Zhong, X.-S., Matsushita, M., Plotkin, J., Riviere, I., & Sadelain, M. (2010) · Molecular Therapy · doi:10.1038/mt.2009.210 · Cited by 543
The CD28-Related Molecule ICOS Is Required for Effective T Cell–Dependent Immune Responses
Coyle, A. J., Lehar, S., Lloyd, C., Tian, J., Delaney, T., Manning, S., Nguyen, T., Burwell, T., Schneider, H., Gonzalo, J. A., et al. (2000) · Immunity · doi:10.1016/s1074-7613(00)00011-x · Cited by 520
Chimeric antigen receptor T-cell therapies for lymphoma
Brudno, J. N., & Kochenderfer, J. N. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.128 · Cited by 516
Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies
Chester, C., Sanmamed, M. F., Wang, J., & Melero, I. (2018) · Blood · doi:10.1182/blood-2017-06-741041 · Cited by 499
Salter, A. I., Ivey, R. G., Kennedy, J. J., Voillet, V., Rajan, A., Alderman, E. J., Voytovich, U. J., Lin, C., Sommermeyer, D., Liu, L., et al. (2018) · Science Signaling · doi:10.1126/scisignal.aat6753 · Cited by 495
Pulè, M. A., Straathof, K. C., Dotti, G., Heslop, H. E., Rooney, C. M., & Brenner, M. K. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.04.016 · Cited by 487
Kowolik, C. M., Topp, M. S., Gonzalez, S., Pfeiffer, T., Olivares, S., Gonzalez, N., Smith, D. D., Forman, S. J., Jensen, M. C., & Cooper, L. J. N. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0160 · Cited by 487
Wilkie, S., van Schalkwyk, M. C. I., Hobbs, S., Davies, D. M., van der Stegen, S. J. C., Pereira, A. C. P., Burbridge, S. E., Box, C., Eccles, S. A., & Maher, J. (2012) · Journal of Clinical Immunology · doi:10.1007/s10875-012-9689-9 · Cited by 478
Finney, H. M., Akbar, A. N., & Lawson, A. D. G. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.1.104 · Cited by 467
Kuwana, Y., Asakura, Y., Utsunomiya, N., Nakanishi, M., Arata, Y., Itoh, S., Nagase, F., & Kurosawa, Y. (1987) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(87)90502-x · Cited by 429
Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel
Porter, D., Frey, N., Wood, P. A., Weng, Y., & Grupp, S. A. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0571-y · Cited by 401
CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo
Song, D.-G., Ye, Q., Poussin, M., Harms, G. M., Figini, M., & Powell, D. J. (2012) · Blood · doi:10.1182/blood-2011-03-344275 · Cited by 355
ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells
Guedan, S., Chen, X., Madar, A., Carpenito, C., McGettigan, S. E., Frigault, M. J., Lee, J., Posey, A. D., Scholler, J., Scholler, N., et al. (2014) · Blood · doi:10.1182/blood-2013-10-535245 · Cited by 353
Davenport, A. J., Cross, R. S., Watson, K. A., Liao, Y., Shi, W., Prince, H. M., Beavis, P. A., Trapani, J. A., Kershaw, M. H., Ritchie, D. S., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1716266115 · Cited by 351
CD28-independent, TRAF2-dependent Costimulation of Resting T Cells by 4-1BB Ligand
Saoulli, K., Lee, S. Y., Cannons, J. L., Yeh, W. C., Santana, A., Goldstein, M. D., Bangia, N., DeBenedette, M. A., Mak, T. W., Choi, Y., et al. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.11.1849 · Cited by 322
Ramos, C. A., Rouce, R., Robertson, C. S., Reyna, A., Narala, N., Vyas, G., Mehta, B., Zhang, H., Dakhova, O., Carrum, G., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.09.009 · Cited by 299
Song, D.-G., Ye, Q., Carpenito, C., Poussin, M., Wang, L.-P., Ji, C., Figini, M., June, C. H., Coukos, G., & Powell, D. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0422 · Cited by 287
Gomes-Silva, D., Mukherjee, M., Srinivasan, M., Krenciute, G., Dakhova, O., Zheng, Y., Cabral, J. M. S., Rooney, C. M., Orange, J. S., Brenner, M. K., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.09.015 · Cited by 285
The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy
Buchan, S. L., Rogel, A., & Al-Shamkhani, A. (2018) · Blood · doi:10.1182/blood-2017-07-741025 · Cited by 276
A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia
Enblad, G., Karlsson, H., Gammelgård, G., Wenthe, J., Lövgren, T., Amini, R. M., Wikstrom, K. I., Essand, M., Savoldo, B., Hallböök, H., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0426 · Cited by 269
The Inducible Costimulator (ICOS) Is Critical for the Development of Human T H 17 Cells
Paulos, C. M., Carpenito, C., Plesa, G., Suhoski, M. M., Varela-Rohena, A., Golovina, T. N., Carroll, R. G., Riley, J. L., & June, C. H. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000448 · Cited by 255
Immune Responses in 4-1BB (CD137)-Deficient Mice
Kwon, B. S., Hurtado, J. C., Lee, Z. H., Kwack, K. B., Seo, S. K., Choi, B. K., Koller, B. H., Wolisi, G., Broxmeyer, H. E., & Vinay, D. S. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.11.5483 · Cited by 221
Curran, K. J., Seinstra, B. A., Nikhamin, Y., Yeh, R., Usachenko, Y., van Leeuwen, D. G., Purdon, T., Pegram, H. J., & Brentjens, R. J. (2015) · Molecular Therapy · doi:10.1038/mt.2015.4 · Cited by 217
So, T., & Croft, M. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.3.1427 · Cited by 210
Wen, T., Bukczynski, J., & Watts, T. H. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.10.4897 · Cited by 207
Zhang, H., Snyder, K. M., Suhoski, M. M., Maus, M. V., Kapoor, V., June, C. H., & Mackall, C. L. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.7.4910 · Cited by 202
Cloning of mouse Ox40: a T cell activation marker that may mediate T-B cell interactions.
Calderhead, D. M., Buhlmann, J. E., van den Eertwegh, A. J. M., Claassen, E., Noelle, R. J., & Fell, H. P. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.151.10.5261 · Cited by 202
Hombach, A. A., Heiders, J., Foppe, M., Chmielewski, M., & Abken, H. (2012) · OncoImmunology · doi:10.4161/onci.19855 · Cited by 200
Mata, M., Gerken, C., Nguyen, P., Krenciute, G., Spencer, D. M., & Gottschalk, S. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0263 · Cited by 179
Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma
Quintarelli, C., Orlando, D., Boffa, I., Guercio, M., Polito, V. A., Petretto, A., Lavarello, C., Sinibaldi, M., Weber, G., Del Bufalo, F., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1433518 · Cited by 163
Chimeric antigen receptor–modified T cells: CD19 and the road beyond
Salter, A. I., Pont, M. J., & Riddell, S. R. (2018) · Blood · doi:10.1182/blood-2018-01-785840 · Cited by 159
Human dendritic cells activate T lymphocytes via a CD40: CD40 ligand‐dependent pathway
McLellan, A. D., Sorg, R. V., Williams, L. A., & Hart, D. N. J. (1996) · European Journal of Immunology · doi:10.1002/eji.1830260603 · Cited by 146
Self-citationKofler, D. M., Chmielewski, M. M., Rappl, G., Hombach, A., Riët, T., Schmidt, A., Hombach, A. A., Wendtner, C., & Abken, H. (2011) · Molecular Therapy · doi:10.1038/mt.2011.9 · Cited by 141
ICOS Ligation Recruits the p50α PI3K Regulatory Subunit to the Immunological Synapse
Fos, C., Salles, A., Lang, V., Carrette, F., Audebert, S., Pastor, S., Ghiotto, M., Olive, D., Bismuth, G., & Nunès, J. A. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.3.1969 · Cited by 133
CD137 (4-1BB) Signalosome: Complexity Is a Matter of TRAFs
Zapata, J. M., Pérez-Chacón, G., Carr-Baena, P., Martínez‐Forero, I., Azpilikueta, A., Otano, I., & Melero, I. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02618 · Cited by 128
Ede, C., Chen, X., Lin, M.-Y., & Chen, Y. Y. (2016) · ACS Synthetic Biology · doi:10.1021/acssynbio.5b00266 · Cited by 124
Weng, J., Lai, P., Qin, L., Lai, Y., Jiang, Z., Luo, C., Huang, X., Wu, S., Shao, D., Deng, C., et al. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0572-x · Cited by 117
Self-citationA Costimulatory Function for T Cell CD40
Munroe, M. E., & Bishop, G. A. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.2.671 · Cited by 108
Toll-like receptor 2 costimulation potentiates the antitumor efficacy of CAR T Cells
Lai, Y., Weng, J., Wei, X., Qin, L., Lai, P., Zhao, R., Jiang, Z., Li, B., Lin, S., Wang, S., et al. (2017) · Leukemia · doi:10.1038/leu.2017.249 · Cited by 105
Harada, Y., Ohgai, D., Watanabe, R., Okano, K., Koiwai, O., Tanabe, K., Toma, H., Altman, A., & Abe, R. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021305 · Cited by 102
Zhi, C., Wei, R., Ma, Q., Shi, L., He, F., Shi, Z., Jin, T., Xie, R., Wei, B., Chen, J., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.01.022 · Cited by 96
Laux, I., Khoshnan, A., Tindell, C., Bae, D. J., Zhu, X., June, C. H., Effros, R. B., & Nel, A. E. (2000) · Clinical Immunology · doi:10.1006/clim.2000.4902 · Cited by 91
Rössig, C., Pulè, M. A., Altvater, B., Saïagh, S., Wright, G. P., Ghorashian, S., Clifton‐Hadley, L., Champion, K. M., Sattar, Z., Popova, B., et al. (2017) · Leukemia · doi:10.1038/leu.2017.39 · Cited by 78
Condomines, M., Arnason, J. E., Benjamin, R., Gunset, G., Plotkin, J., & Sadelain, M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0130518 · Cited by 68
Membrane Rafts in T Cell Activation: A Spotlight on CD28 Costimulation
Zumerle, S., Molon, B., & Viola, A. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01467 · Cited by 55
Chaperot, L., Plumas, J., Jacob, M., Bost, F., Molens, J., Sotto, J., & Bensa, J. (1999) · Experimental Hematology · doi:10.1016/s0301-472x(98)00059-9 · Cited by 49
Functional Improvement of Chimeric Antigen Receptor Through Intrinsic Interleukin-15Rα Signaling
Nair, S., Wang, J., Tsao, S.-T., Liu, Y., Zhu, W. J., Slayton, W. B., Moreb, J. S., Dong, L., & Chang, L. (2018) · Current Gene Therapy · doi:10.2174/1566523218666181116093857 · Cited by 47
Transmembrane domain-mediated Lck association underlies bystander and costimulatory ICOS signaling
Wan, Z., Shao, X., Ji, X., Dong, L., Wei, J., Xiong, Z., Liu, W., & Qi, H. (2018) · Cellular and Molecular Immunology · doi:10.1038/s41423-018-0183-z · Cited by 42
Therapeutic potential of anti-CD137 (4-1BB) monoclonal antibodies
Vinay, D. S., & Kwon, B. S. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2016.1091448 · Cited by 34
Distinct signaling pathways regulate TLR2 co-stimulatory function in human T cells
Chapman, N. M., Bilal, M. Y., Cruz‐Orcutt, N., Knudson, C. J., Madinaveitia, S., Light, J. J., & Houtman, J. C. D. (2012) · Cellular Signalling · doi:10.1016/j.cellsig.2012.11.026 · Cited by 21
Cited by
CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges
Zhang, X., Zhu, L., Zhang, H., Chen, S., & Xiao, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.927153 · Cited by 396
CAR-T design: Elements and their synergistic function
Jayaraman, J., Mellody, M. P., Hou, A. J., Desai, R. P., Fung, A. W., Pham, A. H. T., Chen, Y. Y., & Zhao, W. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102931 · Cited by 374
Siegler, E. L., & Kenderian, S. S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01973 · Cited by 282
CAR-T cell performance: How to improve their persistence?
López-Cantillo, G., Urueña, C., Camacho, B. A., & Ramírez-Segura, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.878209 · Cited by 207
RETRACTED ARTICLE: Hurdles to breakthrough in CAR T cell therapy of solid tumors
Marofi, F., Achmad, H., Bokov, D., Abdelbasset, W. K., Alsadoon, Z., Chupradit, S., Suksatan, W., Shariatzadeh, S., Hasanpoor, Z., Yazdanifar, M., et al. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-02819-x · Cited by 47
Retracted
Metadata
- Authors
- Weinkove, R., George, P., Dasyam, N., & McLellan, A. D.
- Venue
- Clinical & Translational Immunology
- Publisher
- Wiley
- Published
- 2019-01
- Volume
- 8
- Issue
- 5
- Pages
- e1049-e1049
- ISSN
- 2050-0068 (ISSN-L)
- OpenAlex
- W2944669426
- Cited by
- 324
- References
- 75
- FWCI
- 15.05
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.